Trial of Antibody Responses by Vitamin Supplementation
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Streptococcus pneumoniae, commonly called pneumococcus, can cause a wide range of diseases in children from mild ear infections to deadly pneumonia or meningitis. Vaccination is currently the single best way to protect children. Nutrition, especially the amount of vitamin A, may play a role in how well your body responds to infection or a vaccine. We call this an immune response. This research will look to see if children who take a vitamin with their vaccine have a better immune response than children who do not take a vitamin with their vaccine.
Primary Objective
To evaluate the influence of vitamin A supplementation on Prevnar vaccine immunogenicity based on changes in antibody scores in a commercial ELISA at Day 21 (after a booster vaccine dose) compared to pre-vaccine values.
Secondary Objectives
- To evaluate the relationship between baseline vitamin levels and pneumococcal or hepatitis A vaccine antibody responses (based on in commercial ELISAs) at Days 0 and 21.
- To evaluate the influence of vitamin A supplementation on hepatitis vaccine immunogenicity based on changes in antibody scores in a commercial ELISA at Day 21 compared to pre-vaccine values.
- To evaluate relationships between total serum antibodies (based on individual IgM, IgG1, IgG2, IgG3, IgG4, and IgA scores in a Luminex assay) at Day 0 and changes between Days 0 and 21 with baseline (Day 0) vitamin levels in young children, and with vitamin A supplementation.
Full description
Children between the ages of 1 and 4 years old (inclusive) will be enrolled. All will receive PCV and hepatitis A vaccination. Those randomized to the treatment arm will receive 10,000 IU orally at the time of vaccination, while those randomized to the control arm will only receive vaccines. Vitamin levels and antibody responses towards the vaccines will be measured at screening, Day 0 (vaccination day) and Day +21. Children will be randomized using a stratified permuted block method.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Between 1 and 4 years old (inclusive) at the time of enrollment
- Fully weaned from breast-feeding or formula-feeding for at least 4 weeks prior to vaccination date (Day 0).
- Received at least 2 doses of Prevnar-13 vaccination
- Parent or legal guardian willing and able to provide informed consent.
Exclusion criteria
- Current use of investigational or immunosuppressive drugs (e.g., steroids) at the time of enrollment
- Parent/guardian planning to continue (or initiate) the administration of daily vitamin A, vitamin D, or multivitamin to the child during the study period.
- Evidence of developmental delay or evolving neurological disorders at screening.
- Current use of antibiotics or antivirals at enrollment.
- Currently receiving cancer related treatment.
- History of heart, kidney, or chronic respiratory condition (e.g., asthma) conditions.
- History of diabetes.
- Acute febrile illness [e.g., >100.0F (37.8oC) oral] illness within 3 days prior to enrollment.
- Received a previous PCV13 vaccine within 2 months of the enrollment date (Day 0).
- Received hepatitis A vaccine previously.
- Ever had a life-threatening allergic reaction to a dose of PCV13 vaccine, to an earlier pneumococcal vaccine called PCV7, or to any vaccine containing diptheria toxoid (for example, DTaP).
Trial design
Primary purpose
Allocation
Interventional model
Masking
22 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Nehali Patel, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal